Effect of Evolocumab or Ezetimibe Added to Moderate or HighIntensity Statin Therapy on LDLC Lowering in Patients With Hypercholesterolemia The LAPLACE2 Randomized Clinical Trial

ImportanceIn phase 2 studies evolocumab a fully human monoclonal antibody to PCSK9 reduced LDLC levels in patients receiving statin therapy.ObjectiveTo evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate vs highint...